MAVIRET (glecaprevir /pibrentasvir), fixed direct-acting antiviral combination
Reason for request
High clinical benefit for the treatment of chronic hepatitis C virus genotypes 1 to 6 and minor clinical added value compared to other previously available direct-acting antiviral combinations
-
MAVIRET has been granted a marketing authorisation for the treatment of chronic hepatitis C in adults infected with hepatitis C virus (HCV) genotypes 1 to 6.
-
Its pan-genotypic virological efficacy is high, with a treatment duration of 8 to 12 weeks for most patients without cirrhosis or with compensated cirrhosis.
-
Its efficacy has been demonstrated in specific populations such as kidney failure or haemodialysis patients for whom the alternatives are limited.
-
Its safety and resistance profiles are satisfactory but it has a high medicinal interaction potential.
Clinical Benefit
Substantial |
- |
Clinical Added Value
minor |
- |